Mirum Pharmaceuticals Inc
Research Mirum Pharmaceuticals Inc (MIRM) on Bullrun: market cap USD 6.35B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMIRM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.35B
- Financial periodQ2 2026
- RevenueUSD 176.24M
- Net income-USD 67.23M
- Free cash flow-USD 69.28M
- Gross margin82.8%
Valuation Snapshot
latest market cap is USD 6.35B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 521.31M | -USD 23.36M | USD 54.87M | 80.8% | -0.47 | USD 296.68M | USD 319.45M | USD 314.69M |
| FY2024 | USD 336.89M | -USD 87.94M | USD 9.33M | 75.8% | -1.85 | USD 222.50M | USD 317.76M | USD 225.64M |
| FY2023 | USD 186.37M | -USD 163.42M | -USD 71.05M | 74.8% | -4 | USD 286.33M | USD 308.14M | USD 248.67M |
| FY2022 | USD 77.06M | -USD 135.67M | -USD 120.41M | n/a | -4.02 | USD 28.00M | USD 2.27M | USD 142.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.35B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.10B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.00B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.38B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 718.97M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 487.79M | n/a | n/a | n/a |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mirum Pharmaceuticals Inc's market cap?
Mirum Pharmaceuticals Inc's market capitalization is USD 6.35B.
What does Mirum Pharmaceuticals Inc do?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.